Goldman Sachs Group Inc. Has $837,000 Stock Holdings in Entrada Therapeutics, Inc. $TRDA

Key Points

• Goldman Sachs significantly reduced its stake in Entrada Therapeutics by 67.6%, owning now 92,540 shares worth $837,000 as of the latest SEC filing.
• Institutional investors collectively own 86.39% of Entrada Therapeutics, indicating strong interest from large investors in the company's stock.
• Entrada Therapeutics reported a loss of ($1.04) EPS for the last quarter, falling short of the consensus estimate, alongside a revenue of $1.98 million compared to expected $8.17 million.

Goldman Sachs Group Inc. cut its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 67.6% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 92,540 shares of the company's stock after selling 192,732 shares during the period. Goldman Sachs Group Inc. owned 0.24% of Entrada Therapeutics worth $837,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of TRDA. Merck & Co. Inc. bought a new position in shares of Entrada Therapeutics during the first quarter worth approximately $15,728,000. Wellington Management Group LLP increased its stake in shares of Entrada Therapeutics by 2.1% during the first quarter. Wellington Management Group LLP now owns 1,053,314 shares of the company's stock worth $9,522,000 after purchasing an additional 21,488 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Entrada Therapeutics by 28.1% during the first quarter. Massachusetts Financial Services Co. MA now owns 86,310 shares of the company's stock worth $780,000 after purchasing an additional 18,926 shares during the period. American Century Companies Inc. increased its stake in shares of Entrada Therapeutics by 13.5% during the first quarter. American Century Companies Inc. now owns 67,793 shares of the company's stock worth $613,000 after purchasing an additional 8,083 shares during the period. Finally, Nuveen LLC bought a new position in shares of Entrada Therapeutics during the first quarter worth approximately $606,000. 86.39% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Entrada Therapeutics news, Director Kush Parmar sold 75,000 shares of Entrada Therapeutics stock in a transaction dated Friday, June 27th. The stock was sold at an average price of $6.91, for a total transaction of $518,250.00. Following the transaction, the director directly owned 1,113,092 shares of the company's stock, valued at approximately $7,691,465.72. The trade was a 6.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Ventures V. L.P. 5Am sold 55,735 shares of Entrada Therapeutics stock in a transaction dated Friday, June 27th. The stock was sold at an average price of $6.91, for a total value of $385,128.85. Following the completion of the transaction, the insider directly owned 3,220,287 shares of the company's stock, valued at approximately $22,252,183.17. This trade represents a 1.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 254,000 shares of company stock worth $1,782,000 over the last ninety days. Company insiders own 7.59% of the company's stock.

Entrada Therapeutics Trading Down 3.6%

Shares of TRDA opened at $5.09 on Wednesday. The company has a market capitalization of $193.61 million, a PE ratio of -2.86 and a beta of -0.13. Entrada Therapeutics, Inc. has a 12 month low of $4.93 and a 12 month high of $21.79. The stock's 50-day moving average price is $5.64 and its two-hundred day moving average price is $7.38.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.18). The company had revenue of $1.98 million for the quarter, compared to analyst estimates of $8.17 million. Entrada Therapeutics had a negative return on equity of 17.81% and a negative net margin of 92.30%. Equities research analysts predict that Entrada Therapeutics, Inc. will post 1.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TRDA has been the topic of a number of analyst reports. Wall Street Zen downgraded Entrada Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Zacks Research raised Entrada Therapeutics to a "hold" rating in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $25.67.

Entrada Therapeutics Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.

Want to see what other hedge funds are holding TRDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.